MenopauseSkin wrinkles and rigidity in early postmenopausal women vary by race/ethnicity: baseline characteristics of the skin ancillary study of the KEEPS trial
Section snippets
Materials and methods
The KEEPS trial is a multicenter, double-blind, randomized placebo-controlled trial designed to compare the effects of early initiation of oval versus transdermal E, each with cyclic P, on cardiovascular end points. Subjects enrolled in the parent KEEPS trial were offered participation in this ancillary skin study to evaluate the effects of HT on skin aging at two of the nine participating sites (Yale University, New Haven, CT and Albert Einstein College of Medicine, Bronx, NY) under approved
Demographics
Baseline skin assessment was completed in 106 participants from KEEPS. Mean age of these participants was 53.3 years (±2.7 years) and had an average duration of 1.8 years (±1.0 year) since menopause. Baseline demographics were also analyzed by racial group, which were broken into black (n = 21), white (n = 65), and other (n = 16). Race was not recorded for three participants (Table 1). Past or current tobacco smoking, age and years since onset of menopause were comparable among racial groups,
Discussion
Although the effects of E on the skin are widely studied, characterization of the skin near the menopausal transition is lacking. Furthermore, data on racial differences in skin aging are sparse and conflicting (33). In the present study we describe skin characteristics in recently menopausal women, and also delineate skin differences that exist among racial groups. Our finding that black women have significantly fewer wrinkles overall is the first to quantify such a racial difference in
References (33)
- et al.
Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study
Maturitas
(1995) - et al.
Effects of postmenopausal hypoestrogenism on skin collagen
Maturitas
(1999) - et al.
Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response
Am J Pathol
(1999) Aging, traumatic injury, and estrogen treatment
Exp Gerontol
(2005)A dermatologist’s opinion on hormone therapy and skin aging
Fertil Steril
(2005)- et al.
Long-term effects of hormone therapy on skin rigidity and wrinkles
Fertil Steril
(2005) - et al.
Ethnic skin: overview of structure and function
J Am Acad Dermatol
(2003) - et al.
Ethnic differences in the structural properties of facial skin
J Dermatol Sci
(2009) Skin of color: biology, structure, function, and implications for dermatologic disease
J Am Acad Dermatol
(2002)- et al.
Use of a durometer to assess skin hardness
J Am Acad Dermatol
(1993)
Use of a durometer to measure the degree of skin induration in lipodermatosclerosis
J Am Acad Dermatol
The direct effect of steroids on the senile human skin
J Gerontol
Studies on aging: correlation of skin morphology with age and hormone excretion
J Gerontol
[Effect of oral estrogen treatment with estriol succinate on the skin of castrated women]
Z Haut Geschlechtskr
Long-term effects of the menopause and sex hormones on skin thickness
Br J Obstet Gynaecol
Skin thickness in different menopausal status
J Med Assoc Thai
Cited by (28)
The post-mortem resilience of facial creases and the possibility for use in identification of the dead
2014, Forensic Science InternationalCitation Excerpt :The lack of dermal elasticity increases the likelihood of skin sagging. However, research utilising a durometer showed no correlation between body mass index (BMI) and skin wrinkles at eleven locations on the face in early postmenopausal women [26]. Some facial creases are utilised for identification of the living [27], but the use of facial creases for identification of the dead has not been previously studied.
Use of a novel indentometer to evaluate skin stiffness in healthy and diseased human skin
2023, Skin Research and TechnologySkin Aging Exposome in Skin of Color Populations: Review of the Literature
2023, Dermatologic Surgery
E.W. has nothing to disclose. L.P. has nothing to disclose. T.A. has nothing to disclose. R.M. has nothing to disclose. R.F. has nothing to disclose. H.A. has nothing to disclose. M.H. has nothing to disclose. N.S. has nothing to disclose. H.S.T. has nothing to disclose.
Supported by the Kronos Longevity Research Institute; the Reproductive Scientist Development Program NIH K12HD00849 and The Berlex Foundation to Erin Wolff; and the National Institutes of Health grant U54 HD052668 to Hugh S. Taylor.